Raymond James Financial Inc. Takes $746,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Raymond James Financial Inc. purchased a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 131,505 shares of the company’s stock, valued at approximately $746,000. Raymond James Financial Inc. owned approximately 0.24% of Voyager Therapeutics at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in VYGR. Picton Mahoney Asset Management boosted its holdings in shares of Voyager Therapeutics by 71.1% during the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock worth $33,000 after buying an additional 2,444 shares during the period. Virtu Financial LLC bought a new stake in shares of Voyager Therapeutics during the fourth quarter worth $100,000. Legal & General Group Plc increased its holdings in shares of Voyager Therapeutics by 65.2% during the fourth quarter. Legal & General Group Plc now owns 19,245 shares of the company’s stock worth $109,000 after buying an additional 7,597 shares in the last quarter. SG Americas Securities LLC lifted its stake in shares of Voyager Therapeutics by 86.7% in the 4th quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock valued at $131,000 after acquiring an additional 10,704 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Voyager Therapeutics by 23.9% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 39,313 shares of the company’s stock valued at $223,000 after acquiring an additional 7,573 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analysts Set New Price Targets

VYGR has been the topic of several recent research reports. Wedbush reiterated an “outperform” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group reduced their price target on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday, March 12th. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research note on Tuesday, April 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $13.97.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of the firm’s stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the completion of the sale, the chief executive officer now directly owns 430,931 shares of the company’s stock, valued at $1,478,093.33. This trade represents a 2.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 4.53% of the company’s stock.

Voyager Therapeutics Trading Down 6.9 %

Voyager Therapeutics stock opened at $3.25 on Wednesday. Voyager Therapeutics, Inc. has a 1-year low of $2.75 and a 1-year high of $9.55. The firm has a market capitalization of $179.77 million, a price-to-earnings ratio of 4.58 and a beta of 0.95. The firm’s fifty day moving average price is $3.56 and its two-hundred day moving average price is $4.99.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. On average, research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.